Von dem Buch The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis haben wir 2 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: Terhechte, Oliver: The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis (ISBN: 9783346239976) in Englisch, Taschenbuch.Nur diese Ausgabe anzeigen…
100%: Oliver Terhechte: The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis (ISBN: 9783346239969) 2017, in Englisch, auch als eBook.Nur diese Ausgabe anzeigen…
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis
9 Angebote vergleichen
Bester Preis: Fr. 15.65 (€ 15.99)¹ (vom 01.10.2020)1
Symbolbild
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis (Paperback) (2020)
~EN PB NWISBN: 9783346239976 bzw. 3346239977, vermutlich in Englisch, GRIN Verlag, Germany, Taschenbuch, neu.
Von Händler/Antiquariat, The Book Depository EURO [60485773], London, United Kingdom.
Language: English. Brand new Book. Bachelor Thesis from the year 2017 in the subject Economics - Finance, grade: 2,0, University of Mannheim, language: English, abstract: The thesis analyses the merger of Pfizer Inc. and Allergan in 2015. The goal of the thesis is to value Allergan using multiples at the time of a takeover announcement and to examine whether the offer price is fair. The thesis further examines the price reactions of Allergan, Pfizer, and optionally their competitors on the announcement date using event study analysis.On November 23, 2015, Pfizer Inc. and Allergan, Plc publicly announced their intention to merge to form the world's largest drug maker. The boards of both companies had ratified the deal worth approximately $160 billion the day before. This sum would make it not only the largest pharmaceutical deal ever, but also the third largest corporate merger in history.The takeover would also be the largest so-called "inversion" deal to date. These deals consist of a US company buying a foreign rival to adopt their lower tax jurisdictions. To achieve this goal, Dublin-based Allergan would buy the larger New-York based Pfizer in a reverse merger. Just days before the announcement of the merger, the Treasury Department released new rules aiming to curb tax-lowering inversion deals. On April 6, 2016, Pfizer and Allergan announced they would be calling off the merger.
Language: English. Brand new Book. Bachelor Thesis from the year 2017 in the subject Economics - Finance, grade: 2,0, University of Mannheim, language: English, abstract: The thesis analyses the merger of Pfizer Inc. and Allergan in 2015. The goal of the thesis is to value Allergan using multiples at the time of a takeover announcement and to examine whether the offer price is fair. The thesis further examines the price reactions of Allergan, Pfizer, and optionally their competitors on the announcement date using event study analysis.On November 23, 2015, Pfizer Inc. and Allergan, Plc publicly announced their intention to merge to form the world's largest drug maker. The boards of both companies had ratified the deal worth approximately $160 billion the day before. This sum would make it not only the largest pharmaceutical deal ever, but also the third largest corporate merger in history.The takeover would also be the largest so-called "inversion" deal to date. These deals consist of a US company buying a foreign rival to adopt their lower tax jurisdictions. To achieve this goal, Dublin-based Allergan would buy the larger New-York based Pfizer in a reverse merger. Just days before the announcement of the merger, the Treasury Department released new rules aiming to curb tax-lowering inversion deals. On April 6, 2016, Pfizer and Allergan announced they would be calling off the merger.
2
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis (2017)
~EN PB NWISBN: 9783346239976 bzw. 3346239977, vermutlich in Englisch, Grin Verlag Grin Verlag, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, buecher.de GmbH & Co. KG, [1].
Bachelor Thesis from the year 2017 in the subject Economics - Finance, grade: 2,0, University of Mannheim, language: English, abstract: The thesis analyses the merger of Pfizer Inc. and Allergan in 2015. The goal of the thesis is to value Allergan using multiples at the time of a takeover announcement and to examine whether the offer price is fair. The thesis further examines the price reactions of Allergan, Pfizer, and optionally their competitors on the announcement date using event study analysis. On November 23, 2015, Pfizer Inc. and Allergan, Plc publicly announced their intention to merge to form the world's largest drug maker. The boards of both companies had ratified the deal worth approximately 160 billion the day before. This sum would make it not only the largest pharmaceutical deal ever, but also the third largest corporate merger in history. The takeover would also be the largest so-called "inversion" deal to date. These deals consist of a US company buying a foreign rival to adopt their lower tax jurisdictions. To achieve this goal, Dublin-based Allergan would buy the larger New-York based Pfizer in a reverse merger. Just days before the announcement of the merger, the Treasury Department released new rules aiming to curb tax-lowering inversion deals. On April 6, 2016, Pfizer and Allergan announced they would be calling off the merger. 2020 40 S. 5 Farbabb. 210 mm Versandfertig in 6-10 Tagen, Softcover, Neuware, Offene Rechnung (Vorkasse vorbehalten).
Von Händler/Antiquariat, buecher.de GmbH & Co. KG, [1].
Bachelor Thesis from the year 2017 in the subject Economics - Finance, grade: 2,0, University of Mannheim, language: English, abstract: The thesis analyses the merger of Pfizer Inc. and Allergan in 2015. The goal of the thesis is to value Allergan using multiples at the time of a takeover announcement and to examine whether the offer price is fair. The thesis further examines the price reactions of Allergan, Pfizer, and optionally their competitors on the announcement date using event study analysis. On November 23, 2015, Pfizer Inc. and Allergan, Plc publicly announced their intention to merge to form the world's largest drug maker. The boards of both companies had ratified the deal worth approximately 160 billion the day before. This sum would make it not only the largest pharmaceutical deal ever, but also the third largest corporate merger in history. The takeover would also be the largest so-called "inversion" deal to date. These deals consist of a US company buying a foreign rival to adopt their lower tax jurisdictions. To achieve this goal, Dublin-based Allergan would buy the larger New-York based Pfizer in a reverse merger. Just days before the announcement of the merger, the Treasury Department released new rules aiming to curb tax-lowering inversion deals. On April 6, 2016, Pfizer and Allergan announced they would be calling off the merger. 2020 40 S. 5 Farbabb. 210 mm Versandfertig in 6-10 Tagen, Softcover, Neuware, Offene Rechnung (Vorkasse vorbehalten).
3
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis (2017)
~EN NW EB DLISBN: 9783346239969 bzw. 3346239969, vermutlich in Englisch, GRIN Verlag, neu, E-Book, elektronischer Download.
Lieferung aus: Deutschland, Versandkostenfrei.
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis: Bachelor Thesis from the year 2017 in the subject Economics - Finance, grade: 2,0, University of Mannheim, language: English, abstract: The thesis analyses the merger of Pfizer Inc. and Allergan in 2015. The goal of the thesis is to value Allergan using multiples at the time of a takeover announcement and to examine whether the offer price is fair. The thesis further examines the price reactions of Allergan, Pfizer, and optionally their competitors on the announcement date using event study analysis. On November 23, 2015, Pfizer Inc. and Allergan, Plc publicly announced their intention to merge to form the world`s largest drug maker. The boards of both companies had ratified the deal worth approximately $160 billion the day before. This sum would make it not only the largest pharmaceutical deal ever, but also the third largest corporate merger in history. The takeover would also be the largest so-called `inversion` deal to date. These deals consist of a US company buying a foreign rival to adopt their lower tax jurisdictions. To achieve this goal, Dublin-based Allergan would buy the larger New-York based Pfizer in a reverse merger. Just days before the announcement of the merger, the Treasury Department released new rules aiming to curb tax-lowering inversion deals. On April 6, 2016, Pfizer and Allergan announced they would be calling off the merger. Englisch, Ebook.
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis: Bachelor Thesis from the year 2017 in the subject Economics - Finance, grade: 2,0, University of Mannheim, language: English, abstract: The thesis analyses the merger of Pfizer Inc. and Allergan in 2015. The goal of the thesis is to value Allergan using multiples at the time of a takeover announcement and to examine whether the offer price is fair. The thesis further examines the price reactions of Allergan, Pfizer, and optionally their competitors on the announcement date using event study analysis. On November 23, 2015, Pfizer Inc. and Allergan, Plc publicly announced their intention to merge to form the world`s largest drug maker. The boards of both companies had ratified the deal worth approximately $160 billion the day before. This sum would make it not only the largest pharmaceutical deal ever, but also the third largest corporate merger in history. The takeover would also be the largest so-called `inversion` deal to date. These deals consist of a US company buying a foreign rival to adopt their lower tax jurisdictions. To achieve this goal, Dublin-based Allergan would buy the larger New-York based Pfizer in a reverse merger. Just days before the announcement of the merger, the Treasury Department released new rules aiming to curb tax-lowering inversion deals. On April 6, 2016, Pfizer and Allergan announced they would be calling off the merger. Englisch, Ebook.
4
Symbolbild
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis (2020)
~EN NW RPISBN: 9783346239976 bzw. 3346239977, vermutlich in Englisch, GRIN Verlag, neu, Nachdruck.
Von Händler/Antiquariat, Books2Anywhere [190245], Fairford, GLOS, United Kingdom.
New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
5
Symbolbild
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis (2017)
~EN PB NW RPISBN: 9783346239976 bzw. 3346239977, vermutlich in Englisch, GRIN Verlag, Taschenbuch, neu, Nachdruck.
Von Händler/Antiquariat, Ria Christie Collections [59718070], Uxbridge, United Kingdom.
PRINT ON DEMAND Book; New; Publication Year 2017; Fast Shipping from the UK.
PRINT ON DEMAND Book; New; Publication Year 2017; Fast Shipping from the UK.
6
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis
~EN PB NWISBN: 3346239977 bzw. 9783346239976, vermutlich in Englisch, GRIN Verlag, Taschenbuch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
7
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis
~EN NWISBN: 3346239977 bzw. 9783346239976, vermutlich in Englisch, Droemer, München, Deutschland, neu.
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis ab 15.99 EURO.
8
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis
~EN NW EB DLISBN: 9783346239969 bzw. 3346239969, vermutlich in Englisch, Droemer, München, Deutschland, neu, E-Book, elektronischer Download.
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis ab 14.99 EURO.
9
The (failed) Acquisition of Allergan by Pfizer. Multiples Valuation and Event Study Analysis (2020)
EN PB NWISBN: 9783346239976 bzw. 3346239977, in Englisch, 40 Seiten, GRIN Verlag, Taschenbuch, neu.
Neu ab: 15,99 € (2 Angebote)
Zu den weiteren 2 Angeboten bei Amazon.de
Lieferung aus: Deutschland, Gewöhnlich versandfertig in 3 bis 4 Tagen. Tatsächliche Versandkosten können abweichen.
Von Händler/Antiquariat, Books on Demand GmbH.
GRIN Verlag, Taschenbuch, Publiziert: 2020-08-04T00:00:01Z, Produktgruppe: Book.
Von Händler/Antiquariat, Books on Demand GmbH.
GRIN Verlag, Taschenbuch, Publiziert: 2020-08-04T00:00:01Z, Produktgruppe: Book.
Lade…